ID

35259

Description

Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults; ODM derived from: https://clinicaltrials.gov/show/NCT02476617

Lien

https://clinicaltrials.gov/show/NCT02476617

Mots-clés

Versions (1)
  1. 25/02/2019 25/02/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

25 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Chronic Hepatitis C NCT02476617

Anglais

Eligibility Chronic Hepatitis C NCT02476617

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. screening laboratory result indicating hcv gt1a infection.
Description

Hepatitis C Genotype Laboratory test result

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019196
UMLS CUI [1,2]
C0017431
UMLS CUI [1,3]
C0587081
2. chronic hcv infection.
Description

Hepatitis C, Chronic

Type de données

boolean

Alias
UMLS CUI [1]
C0524910
3. subjects must be non-cirrhotic.
Description

Study Subject Non-cirrhotic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0439687
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
Description

Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure

Type de données

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2]
C1875630
UMLS CUI [3,1]
C1875630
UMLS CUI [3,2]
C0162643
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
Description

Human leukocyte antigen allele Specific

Type de données

boolean

Alias
UMLS CUI [1,1]
C0555907
UMLS CUI [1,2]
C0205369
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. women who are pregnant or breastfeeding.
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
Description

Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay

Type de données

boolean

Alias
UMLS CUI [1,1]
C0149709
UMLS CUI [1,2]
C0020980
UMLS CUI [2,1]
C0920548
UMLS CUI [2,2]
C0020980
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
Description

Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C

Type de données

boolean

Alias
UMLS CUI [1,1]
C1704258
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1548788
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C1548788
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0019196
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
Description

Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C3274035
UMLS CUI [3]
C4324240
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0982327
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0035525
UMLS CUI [6,1]
C0332157
UMLS CUI [6,2]
C3712108
UMLS CUI [7,1]
C0332157
UMLS CUI [7,2]
C3852670
UMLS CUI [8,1]
C0332157
UMLS CUI [8,2]
C3852512
UMLS CUI [9]
C0013230
5. history or solid organ transplant.
Description

Solid organ transplant

Type de données

boolean

Alias
UMLS CUI [1]
C0730400
6. screening laboratory analysis that shows abnormal results.
Description

Laboratory test result abnormal

Type de données

boolean

Alias
UMLS CUI [1]
C0438215
Retour au début de la page

Similar models

Eligibility Chronic Hepatitis C NCT02476617

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis C Genotype Laboratory test result
Item
1. screening laboratory result indicating hcv gt1a infection.
boolean
C0019196 (UMLS CUI [1,1])
C0017431 (UMLS CUI [1,2])
C0587081 (UMLS CUI [1,3])
Hepatitis C, Chronic
Item
2. chronic hcv infection.
boolean
C0524910 (UMLS CUI [1])
Study Subject Non-cirrhotic
Item
3. subjects must be non-cirrhotic.
boolean
C0681850 (UMLS CUI [1,1])
C0439687 (UMLS CUI [1,2])
Therapy naive | PEGINTERFERON/RIBAVIRIN | PEGINTERFERON/RIBAVIRIN Treatment failure
Item
4. subjects must be treatment-naïve or have documentation that they were adherent to prior pegifn/rbv combination therapy and meet the criteria of prior pegifn/rbv treatment failure.
boolean
C0919936 (UMLS CUI [1])
C1875630 (UMLS CUI [2])
C1875630 (UMLS CUI [3,1])
C0162643 (UMLS CUI [3,2])
Human leukocyte antigen allele Specific
Item
5. subjects must meet specific human leukocyte antigen (hla) allele requirements.
boolean
C0555907 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. women who are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hepatitis B surface antigen positive Immunoassay | HIV antibody positive Immunoassay
Item
2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay.
boolean
C0149709 (UMLS CUI [1,1])
C0020980 (UMLS CUI [1,2])
C0920548 (UMLS CUI [2,1])
C0020980 (UMLS CUI [2,2])
Abnormality Study Subject Participation Status Inappropriate | Comorbidity Study Subject Participation Status Inappropriate | Exception Hepatitis C
Item
3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment.
boolean
C1704258 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1548788 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0019196 (UMLS CUI [3,2])
Study Subject Participation Status | Interventional Study | Anti-hepatitis C (HCV) Agents | Exception PEGINTERFERON | Exception Ribavirin | Exposure to ABT-450 | Exposure to Ombitasvir | Exposure to Dasabuvir | Investigational New Drugs
Item
4. current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-hcv agents other than pegifn or rbv (including previous exposure to abt-450, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration.
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
C4324240 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0982327 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0035525 (UMLS CUI [5,2])
C0332157 (UMLS CUI [6,1])
C3712108 (UMLS CUI [6,2])
C0332157 (UMLS CUI [7,1])
C3852670 (UMLS CUI [7,2])
C0332157 (UMLS CUI [8,1])
C3852512 (UMLS CUI [8,2])
C0013230 (UMLS CUI [9])
Solid organ transplant
Item
5. history or solid organ transplant.
boolean
C0730400 (UMLS CUI [1])
Laboratory test result abnormal
Item
6. screening laboratory analysis that shows abnormal results.
boolean
C0438215 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial